TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8814098
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 500 mg/day
Study: 28125598
Drug: No corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroid therapy
Study: 18410562
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus (strains E/N, Oxy and Pen) administered at 2 x 10(10) colony forming units, orally twice daily during antibiotic treatment
Study: 12790964
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical injection sclerotherapy (Group 1)
Study: 3875955
Drug: Maternal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal oxygen inhalation
Study: 3875955
Drug: Oral long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral long-term tocolysis
Study: 29059389
Drug: IMB model-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMB model-based intervention plus nicotine replacement therapy
Study: 25193393
Drug: Polypill (containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg)
Study: 25193393
Drug: 3 drugs
Normalized name: goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 drugs given separately (control group)
Study: 22525485
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl nitrate (GTN) 0.4 mg
Study: 10192668
Drug: Topical anesthetics
Normalized name: topical anesthetics (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetics and vasoconstrictors (phenylephrine 0.5%, 2% lidocaine jelly, 2% tetracaine, 14% benzocaine)
Study: 7590720
Drug: Clindamycin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 2% cream (5 grams daily for 3 days)
Study: 91481
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g L-tryptophan
Study: 31719084
Drug: Lifestyle Africa
Normalized name: African Pygeum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle Africa intervention (17 weekly sessions delivered by trained community health workers, including text messaging and Motivational Interviewing training)
Study: 21916989
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (20 mg rabeprazole and 1 g amoxicillin, twice daily for the first 5 days, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole, twice daily for the remaining 5 days)
Study: 21916989
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (20 mg rabeprazole, 500 mg clarithromycin, and 1 g amoxicillin, twice daily for 7 days)
Study: 19533009
Drug: Both incontinence
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both incontinence pessary and behavioral therapy
Study: 14970962
Drug: modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint-induced movement therapy (mCIMT)
Study: 10373140
Drug: Omeprazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (1 mg/kg/day or 2 mg/kg/day)
Study: 7888256
Drug: Cold air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold air inhalation during exercise testing
Study: 2091873
Drug: Genapol stabilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genapol stabilized human insulin (HOE 21 PH H‐TRONIN)
Study: 30914385
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (40 IU, 100 IU, 160 IU)
Study: 17080879
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L‐Pop (3M ESPE)
Study: 31046700
Drug: PEG‐IFN alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2b 1.0 μg/kg/wk for 24 weeks
Study: 31046700
Drug: PEG‐IFN alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2b 1.5 μg/kg/wk for 24 weeks
Study: 28538361
Drug: CRP >150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP >150 mg/L
Study: 28538361
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of antibiotic treatment
Study: 7653482
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg/d)
Study: 18800142
Drug: Conventional anti-hypertensive
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-hypertensive treatment
Study: 7836707
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin, 4000 U daily SQ for 7-20 days
Study: 30534176
Drug: Osteopathic visceral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic visceral manipulation (OVM); treatment group (OVMG)
Study: 22720283
Drug: Converted implant‐retained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converted implant‐retained overdenture (IOD)
Study: 16331116
Drug: Felodipine extended
Normalized name: Felodipine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine extended release 5 mg/day
Study: 3046587
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment (CIT)
Study: 30780194
Drug: Half-dose clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose clarithromycin group (esomeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 250 mg bid, bismuth potassium citrate 0.6 g bid) for 14 days
Study: 25070960
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Terutroban and Aspirin
Study: 16217243
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E and Selenium (combination)
Study: 9456279
Drug: sotalol, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: sotalol, 120 mg daily (n = 93)
Study: 9456279
Drug: metoprolol, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol, 75 mg daily (n = 98)
Study: 27258204
Drug: Oral acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetylsalicylic acid 100 mg per day after dinner
Study: 22546942
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + PT (single session of adjunctive phototherapy)
Study: 11082825
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch
Study: 9439492
Drug: sICAM‐1 concentrations
Approvals — FDA: no, EMA: no, PMDA: no
Description: sICAM‐1 concentrations in the highest quartile (> 260 ng/mL)
Study: 2568824
Drug: Drug-free baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free baseline
Study: 357309
Drug: Controlled clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled clinical studies of antirheumatic and antianginal drugs
Study: 26066705
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin pump therapy
Study: 22487079
Drug: Daily insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily insulin requirements
Study: 15892085
Drug: Adacolumn® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adacolumn® treatment
Study: 15892085
Drug: G-1 beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-1 beads (in vitro)
Study: 1923397
Drug: Daily chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chlorhexidine rinsing (0.12% solution)
Study: 1923397
Drug: Weekly chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly chlorhexidine rinsing (0.12% solution)
Study: 18815665
Drug: Amiodarone (AMD)
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiodarone (AMD) treatment for more than 24 months
Study: 10548998
Drug: Satisfaction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satisfaction with psychopharmacological treatment
Study: 8786016
Drug: ALA 1200
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA 1200 mg
Study: 7044467
Drug: lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipid-lowering therapy by diet and drugs
Study: 25224684
Drug: Sonic nebulization
Normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonic nebulization (Pulmicort, 2 × 1 mg/4 mL)
Study: 20859313
Drug: Cervical medial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical medial branch blocks with bupivacaine and steroid (Group II)
Study: 7484858
Drug: Intravenous dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dofetilide at doses of 3.0 to 15.0 micrograms/kg
Study: 7484858
Drug: Intravenous dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dofetilide at a dose of 1.5 micrograms/kg
Study: 29987587
Drug: Bilateral botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral botulinum toxin (BT) therapy
Study: 22733398
Drug: Triptorelin pamoate
Normalized name: Triptorelin Pamoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin pamoate (TP) at a dose of 11.5 mg at 3-month intervals until documented progression
Study: 24030685
Drug: Milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 100 mg/day
Study: 10515676
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 mg twice weekly associated with cyclic medroxyprogesterone acetate 10 mg daily (n = 10)
Study: 10515676
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg administered orally once a day (n = 11)
Study: 9701421
Drug: levodropropizine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodropropizine (75 mg t.i.d.; 7 days)
Study: 9701421
Drug: dihydrocodeine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihydrocodeine (10 mg t.i.d.; 7 days)
Study: 26044701
Drug: Intra-arterial injection
Normalized name: METHOTREXATE 25 mg in 1 mL INTRA-ARTERIAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial injection of autologous bone marrow mononuclear cells (2×10^6/kg or 5×10^6/kg)
Study: 9506654
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg phenobarbital intravenously over 1 hour
Study: 16931218
Drug: Once every
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once every 2 weeks subcutaneous epoetin beta (group 2w)
Study: 16931218
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly subcutaneous epoetin beta (group 1w)
Study: 12297476
Drug: Nimodipine on
Normalized name: Nimodipine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine on the basis of conventional therapy lasting till 30 days after injuries
Study: 12297476
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy including craniotomy, hemostasis, dehydration, anti-infection and corticosteroid administration
Study: 6602783
Drug: Bepridil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (2 mg/kg, intravenous infusion)
Study: 29107495
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA
Study: 17664499
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT)‐type intervention plus a consultation letter
Study: 17664499
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT)‐type intervention
Study: 12105840
Drug: rFVIIa (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (4 doses: 5, 20, 80, and 120 microg/kg)
Study: 31978429
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled corticosteroids (ICS)
Study: 22985270
Drug: Long-acting β2-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-agonists and anticholinergics
Study: 2678856
Drug: Non-steroid treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid treatment
Study: 2339965
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg every 8 h)
Study: 25010374
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (2.5 mg daily)
Study: 21050319
Drug: Rifaximin 1,100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 1,100 mg once daily for 2 weeks
Study: 21050319
Drug: Rifaximin 1,100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 1,100 mg once daily
Study: 2517009
Drug: Rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (1 mg)
Study: 28859020
Drug: 2-stage nonoperative
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-stage nonoperative treatment with additional diagnostic block if regular 2 weeks medication was not effective
Study: 26553690
Drug: PsA‐TT vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsA‐TT vaccine
Study: 26553682
Drug: PsACWY vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsACWY vaccine
Study: 12544730
Drug: Idraparinux (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idraparinux (2.5, 5, 7.5 or 10 mg)
Study: 27433335
Drug: 6-week self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week self-management training program (manual therapy, education, home exercises) with instructional workbook and video and a pedometer
Study: 19334068
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m², four weekly infusions)
Study: 9510100
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) treatment
Study: 12957701
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation using Integrated Psychological Treatment (IPT)
Study: 8243685
Drug: Kallidinogenase (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallidinogenase (600 units by mouth daily for 12 weeks)
Study: 3519529
Drug: Propranolol (60-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60-320 mg/day)
Study: 30272850
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient supplements
Study: 29428785
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplements only
Study: 29322301
Drug: DHEA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100 mg daily for 4 weeks)
Study: 18832434
Drug: Flupentixol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 0.5 mg
Study: 12397530
Drug: Felted foam
Normalized name: BELT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felted foam therapy
Study: 29052766
Drug: l-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine supplementation (6.4 g orally/day)
Study: 15363419
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (ESI)
Study: 8672931
Drug: Continuous i.v.‐tocolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v.‐tocolysis and oral application of magnesium sulfate
Study: 1792400
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg
Study: 23158128
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus fentanyl 1 µg/ml
Study: 23158128
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus fentanyl 2 µg/ml
Study: 23158128
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus fentanyl 3 µg/ml
Study: 17196293
Drug: peginterferon/ribavirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon/ribavirin therapy
Study: 12472620
Drug: Maca Gelatinizada
Normalized name: MACA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maca Gelatinizada 1,500 mg
Study: 9696953
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg daily for 6 days)
Study: 2684076
Drug: Intramuscular LEFAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular LEFAC (bovine liver extract containing folic acid and cyanocobalamin)
Study: 31135817
Drug: Galcanezumab, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab, 120 mg
Study: 29098381
Drug: Lapatinib 1500-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1500-mg administered orally once daily on study days 4 through 11
Study: 21282539
Drug: Carboplatin (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (one infusion at 7 × (glomerular filtration rate + 25) based on EDTA)
Study: 21282539
Drug: Carboplatin (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (at least 99% of the 7 × AUC dose)
Study: 21282539
Drug: Carboplatin (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (lower doses)
Study: 20137694
Drug: 52-week rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52-week rabeprazole treatment
Study: 11259888
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg potassium diclofenac orally 1 hour preoperatively and placebo 30 minutes postoperatively (Preop group)
Study: 11259888
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg potassium diclofenac 1 hour preoperatively and 25 mg diclofenac 30 minutes postoperatively (Pre+postop group)
Study: 11444676
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nortriptyline (NT) 50 mg
Study: 20151824
Drug: rhTSH Group
Normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhTSH Group (recombinant human thyroid-stimulating hormone administration)
Study: 15795446
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 mg ascorbic acid and 10 microg folate)
Study: 15795446
Drug: Anemic mothers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemic mothers (both treatment and placebo)
Study: 23640612
Drug: Brinzolamide 1%/brimonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC)
Study: 23640612
Drug: Brimonidine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine monotherapy
Study: 21561700
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg per day for patients below 50 kg and 100 mg per day for patients over 50 kg)
Study: 12192663
Drug: HIV patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV patients on anti-viral medication
Study: 2192197
Drug: Continuous 72
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 72 hour infusion (CI) of Adriamycin, 60 mg/m2 every 3 weeks
Study: 31129369
Drug: Non-responders re-randomized
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders re-randomized to step-up treatment
Study: 11573660
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA)
Study: 23490041
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel load
Study: 23490041
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel load
Study: 23490041
Drug: Atorvastatin reload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin reload (80 mg + 40 mg)
Study: 17613274
Drug: Combination tablets
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablets (600mg calcium + 300mg magnesium + 100IU vitamin D3)
Study: 17613274
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate tablets (1000mg calcium)
Study: 11479391
Drug: Methylphenidate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.2 mg/kg) + L-Dopa (2 mg/kg per h)
Study: 7922005
Drug: Control reagent
Normalized name: urinalysis control reagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control reagent combination using IgG1 control antibody labeled with PE.
Study: 5071698
Drug: Frequent review
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent review by the doctor after the first prescription and cautionary advice to the patient
Study: 26607942
Drug: Resveratrol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (500 mg twice daily)
Study: 12136475
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide
Study: 1422715
Drug: Bioptycut 14-G
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bioptycut 14-G (B14)
Study: 1422715
Drug: Tru-Cut 14-G
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tru-Cut 14-G (T14)
Study: 1422715
Drug: Bioptycut 18-G
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioptycut 18-G (B18)
Study: 6094194
Drug: Bromocriptin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptin (2.5 mg, twice daily for 4 days)
Study: 30213173
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no parecoxib administration)